Stock ANTH ANTHERA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Anthera Pharmaceuticals, Inc.

Equities

ANTH

US03674U3005

Delayed OTC Markets
Other stock markets
 03:50:58 2024-04-24 pm EDT 		5-day change 1st Jan Change
0.000001 USD -.--% Intraday chart for Anthera Pharmaceuticals, Inc. -.--% -98.51%
2018 Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from S&P TMI Index CI
2018 Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from NASDAQ Composite Index CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from S&P TMI Index
CI
Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from NASDAQ Composite Index
CI
Anthera Pharmaceuticals, Inc. Reports Top Line Data from the Result Phase 3 Clinical Study of Sollpura
CI
Transcript : Anthera Pharmaceuticals, Inc. - Special Call
Anthera Mulls Acquisitions
CI
Anthera Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2017
CI
Anthera Pharmaceuticals, Inc. Concludes Last Patient Visit in the Phase 3 Result Clinical Study of Sollpura
CI
Anthera Pharmaceuticals, Inc. announced that it has received $15 million in funding from a group of investors
CI
Anthera Pharmaceuticals, Inc. Appoints Patrick Murphy as Senior Vice President, Manufacturing
CI
Anthera Pharmaceuticals, Inc. Announces Positive Outcome of Interim Futility Analysis in the Phase 3 Result Clinical Study of Sollpura
CI
Anthera Pharmaceuticals Announces Completion of Recruitment in the Phase 3 RESULT Clinical Study of Sollpura
CI
Anthera Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017
CI
Anthera Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding from a group of investors
CI
Anthera Pharmaceuticals, Inc. Announces Top Line Final Data from Phase 2 BRIGHT-SC Study of Blisibimod
CI
Anthera Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017
CI
Anthera Pharmaceuticals, Inc. Announces Executive Changes
CI
Anthera Pharmaceuticals, Inc. Announces Commencement of Screening in European Sites in Phase 3 Result Clinical Study of Sollpura
CI
Anthera Pharmaceuticals, Inc.(NasdaqGM:ANTH) dropped from Russell 3000 Index
CI
Anthera Pharmaceuticals, Inc.(NasdaqGM:ANTH) dropped from Russell 2000 Index
CI
Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from Russell 2000 Dynamic Index
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ANTH Stock
  4. News Anthera Pharmaceuticals, Inc.